par Colli, Maikel Luis
;Hill, Jessica L E;Marroquí, Laura
;Chaffey, Jessica;Dos Santos, Reinaldo Sousa;Leete, Pia;Coomans De Brachene, Alexandra
;Paula, Flavia M M;Op De Beeck, Anne
;Castela, Angela;Marselli, Lorella;Krogvold, Lars;Dahl-Jorgensen, Knut;Marchetti, Piero;Morgan, Noel G;Richardson, Sarah J;Eizirik, Decio L. ![](/vufind/images/ULB/publications_list.png)
Référence EBioMedicine, 36, page (367-375)
Publication Publié, 2018-10
![](/vufind/images/ULB/publications_list.png)
![](/vufind/images/ULB/publications_list.png)
![](/vufind/images/ULB/publications_list.png)
![](/vufind/images/ULB/publications_list.png)
![](/vufind/images/ULB/publications_list.png)
Référence EBioMedicine, 36, page (367-375)
Publication Publié, 2018-10
Article révisé par les pairs
Résumé : | Antibodies targeting PD-1 and its ligand PDL1 are used in cancer immunotherapy but may lead to autoimmune diseases, including type 1 diabetes (T1D). It remains unclear whether PDL1 is expressed in pancreatic islets of people with T1D and how is it regulated. |